Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Feb 21, 2013 4:33pm
216 Views
Post# 21024969

RE: Two Days, Two Conferences

RE: Two Days, Two Conferences

SanFran....I either previously missed the CRT conference on their events page, or they just updated their events page sometime this week. That is great news. If you check out the conference web page (https://www.crtmeeting.org/default.aspx) follow the "Atherosclerosis, Plaque Imaging and Lipid Therapy" button and you will see that Norman Wong is scheduled for a 15 minute presentation Monday Feb 25th 4:20 PM EST entitled "Status Report on Clinical Trials with RVX 208, A Novel Mechanism to Increase HDL by Selectively Increasing ApoA-I Synthesis." This session could be good and bad, as it seems there may be talks on CETP inhibitors and HDL infusions in this same session as well.

So despite what RVX said in the past about not talking about SUSTAIN before June, I think the title of Norman's talk begs to differ. Also, Steven Nissen, who is chair of RVX Clinical Steering Committee and who is the IVUS guru, is giving a talk in that session. And H. Bryan Brewer, another RVX Clinical Steering Committee member is giving a talk and moderating a session. 

So perhaps our good news is just around the corner!

Bullboard Posts